Related Experiment Videos
Treatment of chronic myeloid leukaemia: lessons and challenges
1Imperial College at Hammersmith Hospital, London, UK.
Insights
Allogeneic stem cell transplantation offers a potential cure for chronic myeloid leukemia (CML) but is limited to a few patients. Tyrosine kinase inhibitors like imatinib show promise for CML treatment.
Area of Science:
- Hematology
- Oncology
- Leukemia Research
Background:
- Chronic myeloid leukemia (CML) treatment selection is complex.
- Allogeneic stem cell transplantation (allo-SCT) can eradicate CML via graft-versus-leukemia effect but has eligibility and risk limitations.
- Interferon-alpha prolongs survival but has significant toxicity; hydroxyurea is less effective.
- Imatinib mesylate (Gleevec) induces high rates of hematologic and cytogenetic remission in CML.
Purpose of the Study:
- To review factors predicting survival in chronic phase CML patients.
- To compare non-transplant therapies with allo-SCT for CML management.
- To evaluate current treatment options for newly diagnosed chronic phase CML.
Main Methods:
- Review of prognostic factors for survival in CML.
- Comparison of outcomes between allo-SCT and non-transplant therapies.
- Analysis of treatment efficacy and toxicity profiles.
Main Results:
- Allo-SCT provides leukemia eradication but is suitable for a minority of patients and carries risks.
- Interferon-alpha offers some survival benefit over hydroxyurea but with toxicity.
- Imatinib demonstrates high remission rates, but its long-term survival benefit compared to interferon-alpha is not yet established.
- Prognostic factors for survival in non-transplant and transplant settings were reviewed.
Conclusions:
- For selected chronic phase CML patients, allo-SCT soon after diagnosis remains a viable option.
- Further data on imatinib, alone or in combination, may significantly alter future CML treatment strategies.
- The optimal primary treatment for chronic phase CML requires careful consideration of patient eligibility, risks, and emerging therapies.
Abstract:
The choice of primary treatment for patients with chronic myeloid leukaemia diagnosed in chronic phase has become exceedingly difficult. There is little doubt that allogeneic stem cell transplantation (allo-SCT) can eradicate the leukaemia and that a 'graft-versus-leukaemia' effect makes a major contribution to this result; conversely only a minority of patients are eligible for transplant, which still carries an appreciable risk of mortality or protracted morbidity. For the majority of patients interferon-alpha prolongs life to some degree in comparison with hydroxyurea but is associated with considerable toxicity. The newly introduced tyrosine kinase inhibitor imatinib mesylate (imatinib, Glivec) induces complete haematologic remission in almost all cases and is associated with a very high incidence of cytogenetic response; its capacity to prolong life in comparison with interferon-alpha is not yet established. Here we review some factors that predict survival after non-transplant therapy and after allografting for CML in chronic phase. We consider two contrasting options for managing the newly diagnosed patient and conclude that for the present allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients. Further experience with the use of imatinib as a single agent or in combination with other anti-leukemic agents may alter the picture in the near future.